NEW YORK, July 22, 2026
— RE:YOU today announced the launch of its Dual Path Hair Revival
Serum, a daily scalp serum powered by their proprietary NOVOGRO
TM
technology. Alongside the product's release, the company shared positive
interim results from an ongoing independent clinical study that compares RE:YOU
directly against topical minoxidil, a study design that is uncommon in the
beauty industry.
The clinical study underscores the
company's commitment to raising the scientific standard for the hair thinning
category. Despite affecting millions of people, the category has seen few
meaningful scientific breakthroughs in decades. Many products on the market
today rely on repurposed drugs developed decades ago or botanical extracts with
limited scientific validation.RE:YOU was developed from the ground up with one
goal: to create a clinically validated solution designed specifically to tackle
the root causes of hair thinning.
"We were frustrated by how often
clinical studies are designed to generate marketing claims instead of
meaningful evidence," said Lan Tang, Co-Founder of RE:YOU. "Small
sample sizes, placebo comparisons, and selectively reported survey results have
become the norm. Before asking customers to trust our products, we invested in
a rigorous, clinical study that compares RE:YOU directly against the current
gold standard treatment. While the study is still ongoing, these early results
give us confidence that we're building something that can genuinely move the
category forward."
To evaluate the serum, RE:YOU partnered
with an independent third-party clinical research organization to conduct a
randomized, double-blind study involving 190 participants directly against
minoxidil. Rather than relying solely on participant surveys, the study
incorporates dermoscopy image analysis, independent expert grading,
standardized comb tests, and participant-reported outcomes to evaluate changes
in hair density, scalp coverage, fullness, and shedding.
After the first 90 days of treatment,
participants using RE:YOU demonstrated an
18% greater increase in hair
density than those using topical minoxidil
, based on objective machine
analysis.* Seventy percent of participants experienced measurable increases in
hair thickness, while independent clinical experts observed an average
19%
improvement in hair density
and a
15% increase in scalp coverage
,
suggesting fuller-looking hair across treated areas.
The study also found that RE:YOU produced
substantial improvements in hair shedding. Participants experienced an average
58%
reduction in shed hairs
, with 79% showing measurable improvement through
comb test, a standardized hair counting method.* Compared with topical
minoxidil, participants using RE:YOU were
1.7 times more likely to
demonstrate improvement in the overall appearance of hair thinning
,
according to investigator assessments.*
Those objective findings were reflected
in participant experiences as well. After 90 days,
90% of participants
reported thicker-looking hair
,
90% noticed less hair shedding in the
shower
, and
86% reported visible improvements in hair fullness
where
the serum was applied.* More than three-quarters also reported improvements in
the appearance of their hair part, an area many women identify as one of the
earliest visible signs of thinning.* There were no side effects or hair shed
reported.
While the clinical study remains ongoing,
RE:YOU plans to continue monitoring participants to evaluate the durability of
results over a longer treatment period and further characterize the serum's
safety and efficacy profile.
About RE:YOU
RE:YOU is a biotechnology beauty brand
developing a new generation of hair thinning solutions powered by its
proprietary NOVOGRO™ technology. Guided by its belief that better science
creates better results, RE:YOU combines advances in follicle biology with
rigorous clinical study to create highly effective products that deliver an
exceptional experience.
For more information, visit
getreyou.com.
*Based on
interim 90-day results
from an ongoing
randomized, double-blind, independent clinical study involving 190 participants
comparing RE:YOU Dual Path Hair Revival Serum with topical minoxidil. The study
remains ongoing, and additional follow-up data will be collected. Individual
results may vary. These findings have not been reviewed by the U.S. Food and
Drug Administration. RE:YOU Dual Path Hair Revival Serum is not intended to
diagnose, treat, cure, or prevent any disease.
